Teva to Present at the 31st Annual J.P. Morgan Healthcare Conference

  Teva to Present at the 31st Annual J.P. Morgan Healthcare Conference

JPMorgan Healthcare Conference 2013

Business Wire

JERUSALEM -- January 7, 2013

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio
webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA. Dr.
Jeremy Levin, President & CEO, Teva Pharmaceutical Industries Ltd., will
present on Tuesday, January 8, 2013.

        
What:      Teva Presentation at the 31^st Annual J.P. Morgan Healthcare Conference
                                                                                         
Who:       Dr. Jeremy Levin, President and CEO, Teva Pharmaceutical Industries Ltd.
                                                                                         
When:      Tuesday, January 8, 2013 at 10:30 a.m. (PST)
                                                                                         
Where:     http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=TEVA
                                                                                         
           Live over the Internet – log on to the Web at the address above and register
How:       for the event (approximately 10 minutes before). An archive of the webcast will
           be available on Teva’s website.
           

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic drug
maker, with a global product portfolio of more than 850 molecules and a direct
presence in about 60 countries. Teva's branded businesses focus on CNS,
oncology, pain, respiratory and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 46,000 people around the world
and reached $18.3 billion in net revenues in 2011.

Contact:

Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin C. Mannix, 215-591-8912
Israel
Tomer Amitai, 972 (3) 926-7656
or
PR:
United States
Denise Bradley, 215-591-8974
Israel
Shir Altay-Hagoel, 972 (3) 926-7590
 
Press spacebar to pause and continue. Press esc to stop.